InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.56
(
-0.27%
)
Bitcoin
65,148.93
(
0.02%
)
Post# of 97239
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

pharma_trader

Send PM Follow Ignore
Followers 55
Posts 1664
Boards Moderated 0
Alias Born 12/11/2012

pharma_trader

Re: pharma_trader post# 83404

Wednesday, 10/08/2014 10:09:52 AM

Wednesday, October 08, 2014 10:09:52 AM

Post# of 97239
CNAT-Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

SAN DIEGO, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) today announced that its late-breaking abstract was accepted for a poster presentation at The Liver Meeting(R), the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 7-11, 2014. The poster, entitled "Rapid and statistically significant reduction of markers of apoptosis and cell death in subjects with mild, moderate and severe hepatic impairment treated with a single dose of the pan-caspase inhibitor, emricasan," will be presented on Monday, November 10, 2014. The abstract is available at www.aasld.org/.


http://finance.yahoo.com/news/conatus-pharmaceuticals-announces-acceptance-breaking-140000932.html
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up